GFAP and neuromyelitis optica: In the N-MOmentum trial, higher baseline GFAP levels were associated with future neuroinflammatory attacks in neuromyelitis optica spectrum disorder (NMOSD) and responsive to treatment.41 Given that NMOSD pathophysiology has clear astroglial involvement, the GFAP biomarker is well-suited as a study outcome biomarker.